Introduction
============

Glaucoma in various forms occurs in about 2% of the population aged more than 40 years ([@b37-co-2-321]). It affects children and young adults far less frequently than the elderly. It is estimated that in England and Wales, alone, more than 500,000 people suffer from glaucoma and more than 70 million people are affected worldwide ([@b1-co-2-321]) while uncorrected refractive errors remained the major cause of visual impairment (Resnikoff et al 2004). In the great majority of cases the condition takes a chronic, slowly developing course (primary open angle glaucoma: POAG). Studies have demonstrated that about half of all POAG cases remain undiagnosed in the Western developed countries. The risk of POAG is about four times greater for Afro-American people than for Caucasians.

POAG usually affects both eyes and initially produces few symptoms. Eventually, untreated patients may become aware of severely restricted visual fields, or even a loss of central vision in the worst eye. Although blindness from glaucoma is uncommon, it is wholly or partially the third reason to register on the blind register for England and Wales, and is the leading cause of preventable blindness in the UK ([@b2-co-2-321]). When treated, the probability of glaucoma-related blindness, after treatment of both eyes, was estimated at 9% at 20 years after diagnosis ([@b17-co-2-321]). A significant risk factor for glaucoma blindness is advanced loss of vision when the condition is first detected. Appropriate examinations during routine eye tests are therefore essential to detect glaucoma early and prevent significant sight loss.

The annual economic burden of glaucoma in the UK was estimated at £62 million in direct medical costs in 1994 ([@b5-co-2-321]). Total annual UK costs of glaucoma, including direct, indirect and social cost estimated for the Blind Association 'Guide Dog' service reached £27 billion (Guide Dog for the Blind Association).

Observational data show that frequent medication changes increase the costs of glaucoma treatment ([@b19-co-2-321]; [@b7-co-2-321]). Although the daily cost of a drug must be considered when prescribing ([@b16-co-2-321]; [@b12-co-2-321]; [@b36-co-2-321]; [@b29-co-2-321]), the impact of efficacy should not be overlooked as this can diminish the need for other medical resources, such as ophthalmologist visits, surgery, or laser therapy ([@b20-co-2-321]).

Increased intraocular pressure (IOP) is the main risk factor whereas the other causes of glaucomatous optic neuropathy remain unknown. Various strategies in current use decrease IOP and so lower the risk of glaucoma, thereby limiting its development ([@b18-co-2-321]) and controlling progression ([@b14-co-2-321]; [@b21-co-2-321]; [@b32-co-2-321]; [@b34-co-2-321]). Surgery, laser therapy and several classes of pharmacological agents in common use have been introduced in recent decades. Medications include beta-blockers (marketed in the late 1970s), carbonic anhydrase inhibitors (CIAs) in the mid-1990s, and both alpha-2 adrenergic agonists and prostaglandin analogues (PGAs) in the late 1990s. It is an accepted practice to start treatment with a single drug, followed by drug combinations (whether, or not, fixed) after an initial failure. A second-line monotherapy may be also used in case of failure of the first line monotherapy. Randomized clinical trials of brimonidine vs brinzolamide both associated with travoprost showed a better IOP control in the patients treated with travoprost and brinzolamide ([@b25-co-2-321]; [@b11-co-2-321]).

Health authorities increasingly demand documentation showing drug efficacy based on prescriptions in everyday practice ([@b15-co-2-321]). Retrospective cohort studies comparing treatments can be effective strategies to provide such information. Studies using the endpoint of 'persistence' or 'adherence' to treatment are now being applied to glaucoma treatment ([@b8-co-2-321]; [@b23-co-2-321]; [@b4-co-2-321]; [@b39-co-2-321]).

An extensive source of patient data is The United Kingdom General Practitioner Research Database (UK-GPRD) which collects information from a representative sample of general practitioners (GPs) (<http://www.gprd.com/home/>). Glaucoma data, for example, are collected comprehensively because GPs perform a gatekeeper role in the UK. This paper compares the costs and effectiveness of two medications (alpha-2 adrenergic agonists vs carbonic anhydrase inhibitors) each used in combination with a prostaglandin analogue as glaucoma therapy.

Materials and methods
=====================

Data sources
------------

This study extracted data from the UK-GPRD, which is the world's largest computerized database with anonymous longitudinal records of approximately three million patients in primary medical care collected continuously by general practitioners since 1987. Records include demographic information (other than race) on age, gender, medical diagnosis, prescriptions, clinical events, and hospital referrals.

Data management
---------------

The UK-GPRD mainly reports incidences (eg, visits, drugs, comorbidities), hence considerable data management must be performed to extrapolate the prevalence of events.

Treatments are, here, represented by product names and dates of prescription. The main assumption was that carbonic anhydrase inhibitors (CAIs) or alpha-2 agonists were prescribed for a maximum period of 100 days which approximately corresponds to three eye-drop bottles. Initial prescriptions rarely exceeded this quantity. Two consecutive prescriptions for less than 100 days each were presumed to represent renewed therapy. Any other ophthalmic product prescribed during the same period was regarded as an additional treatment.

Patient selection and inclusion
-------------------------------

Three sets of terms were used to identify the UK-GPRD population of patients treated for glaucoma or intra-ocular hypertension, as follows: (1) Diagnosis required specific 'open-angle' and more generic 'glaucoma' terms that excluded specifically 'closed-angle', 'angle closure' and 'glaucoma due to other causes' (eg, trauma); (2) Surgery or laser terms for glaucoma were flagged as specific (eg, 'laser trabeculoplasty' and 'iridectomy for glaucoma') or non-specific (eg, 'iridectomy' not stated as for glaucoma); (3) Medication terms included topical or systemic glaucoma products defined by their active constituents as listed in the British National Formulary.

Patients of either sex were identified by at least one GP visit documenting a clinical referral or test related to a glaucoma diagnostic, surgical or laser term, as above, or a prescription for a specific glaucoma product. Patients with all the following characteristics were included in the analysis: (1) a glaucoma diagnosis (as above), (2) initial treatment with either a CAI + PGA or an alpha-2 agonist + PGA, and (3) follow-up longer than 6 months once the study therapies were begun. Patients with pre-existing CAI or alpha-2 agonist treatments were excluded.

Evaluation criteria
-------------------

Treatment failure was defined as a prescription change replacing or discontinuing the initial medication, or adding a new medication (association). Patients given laser therapy or surgery for glaucoma were regarded as treatment failures.

Statistical methods
-------------------

Statistical analyses used SAS V9.1 software (SAS Institute; North Carolina, USA). Treatment groups were compared at baseline on demography, general comorbidities and eye comorbidities. Continuous variables were compared by a t-test after verifying normality or by a non-parametric Wilcoxon test, in the absence of normality. Discontinuous variables were analyzed by a Chi-square test that was replaced by Fisher's exact permutation test when samples were small. All tests were interpreted two-sided with α = 0.05.

Survival curves by treatment group were estimated using the Kaplan-Meier method, without adjustment. The treatment failure hazard-ratio between alpha-2 agonist and CAI was estimated by a Cox regression, with and without adjustment.

Unbalanced confounding factors of treatment efficacy were adjusted for, using the propensity score method ([@b40-co-2-321]). The propensity score, defined as the conditional probability of being treated with a specific treatment according to the observed covariates, was used to balance covariates in the two treatment groups and so control bias. A logistic regression was performed to estimate a propensity score (probability to be treated with either alpha-2 agonist or CAI) for each patient. Variables (demographics, general and eye comorbidity, time since diagnosis) included in the logistic regression were selected from univariate statistics searching for treatment unbalances. Then, a stepwise algorithm was used to select variables with an entry and exit p-value fixed at 0.10. Quartiles based on the estimated propensity score were created and included in the Cox model to obtain an adjusted estimate of the treatment effect (time to failure).

Collected medical resource utilization was specific to glaucoma and therefore should not be impacted by comorbidities, by definition. The only known factors contributing to cost is patient follow-up duration. Two sets of estimates were obtained by adjusting, or not adjusting, on the duration of follow-up. Adjustment was made by a linear regression model: (1) the simple model only included treatment group (2) the adjusted model included treatment group and unbalanced confounding factors.

Economic evaluation
-------------------

Direct and consequential costs of glaucoma medical care were analyzed from the economic perspective of the UK National Health Service.

The UK-GPRD yielded the following glaucoma information: (1) laser therapy and surgery, (2) hospitalizations for glaucoma, (3) glaucoma medication, (4) visits to GPs and glaucoma specialists, and (5) prescription renewals by telephone. Consumption items were collected for each patient from the prescription to the final follow-up day and included treatment subsequent to medication failure.

Unit costs of medication were taken from the British National Formulary (2005) ([www.bnf.com](www.bnf.com)) and did not include drug discounts. Unit costs for medical procedures (surgery, laser therapy, hospitalization, and consultations) were taken from [@b16-co-2-321] and inflated to the year 2005 by applying the National Health Service inflation rate (Statistics of OECD). Visits to ophthalmologists were costed at £107 per patient hour and follow-up visits were assumed to last 15 minutes ([@b6-co-2-321]). General practitioner visits were costed at £129 per patient hour and follow-up visits were assumed to last 15 minutes ([@b6-co-2-321]). We estimated both the total and annual costs of each treatment regimen.

Results
=======

In total, 54,513 glaucoma patients were selected from the UK-GPRD representing all UK regions. A subgroup of 6,176 patients met our study criteria, comprising 4,792 treated with CAIs + PGAs and 1,384 with alpha-2 agonists + PGAs. The 3:1 of ratio CAIs/alpha-2 agonists showed that CAIs + PGAs were prescribed more frequently for glaucoma than alpha-2 agonists + PGAs.

No statistically significant differences in gender distribution (47.6%) or age (mean 69.0 years) were found at inclusion between patients treated with CAIs or alpha-2 agonists ([Table 1](#t1-co-2-321){ref-type="table"}). However, time since diagnosis was significantly (p \< 0.001) longer for the CAI group, whereas the mean duration of follow-up was significantly (p \< 0.001) longer for alpha-2 agonist group (1,060 days) than the CAI group (838 days).

General health and eye comorbidity data, comprising all prevalent and incident events from entry into the UK-GPRD to the exit date of the present study, are presented in [Table 2](#t2-co-2-321){ref-type="table"}. Statistically significant differences were noted between the two treatment groups. As compared to CAIs, patients treated with alpha-2 agonists experienced more ocular sensory symptoms and general comorbidities, ie, cardiac disorders, immune system disorders, nervous system disorders, psychiatric disorders, and respiratory disorders. Neither category of comorbidities was associated with time to treatment failure.

One year after starting glaucoma medication, patients experienced less treatment failure with CAIs than with alpha-2 agonists ([Table 3](#t3-co-2-321){ref-type="table"}) and this advantage was maintained throughout the subsequent 3 years. Accordingly, the hazard ratio for failure was significantly less with CAIs (OR = 0.82: p \< 0.0001) before adjustment and remained so after adjustment for age, gender, comorbidities, and duration of follow-up (OR = 0.82: p \< 0.001). Time to 50% failure was longer with CAIs (8.5 months). Survival curves are shown in [Figure 1](#f1-co-2-321){ref-type="fig"}.

Most of the patients were followed up until failure of the current treatment-line: both treatments failed for 5,734 of 6,176 patients (92.8%) during the study period ([Table 4](#t4-co-2-321){ref-type="table"}). Second-line treatment for more than half of all patients was a switch to prostaglandin analogues (in monotherapy or in combination, with beta-blockers the next preference) and for 2.9% a switch to surgery or laser therapy.

Average monthly costs associated with CAIs + PGAs were estimated at £33.98 per patient and were close to those of alpha-2 agonists + PGAs, £36.22 ([Table 5](#t5-co-2-321){ref-type="table"}). There was no significant difference between these costs even after adjustment. Average daily costs with CAIs were 98.2% of those with alpha-2 agonists. The adjusted annual cost difference of a patient receiving CAI treatment was only £27.26 less than for an alpha-2 agonist.

Discussion
==========

The use of carbonic anhydrase inhibitors and prostaglandin analogues was compared in this study with alpha-2 adrenergic agonists and prostaglandin analogues during everyday UK general practice.

Many researchers claim that non-randomized studies lead to unreliable results and advocate the unique use of randomized controlled trials (RCTs) ([@b9-co-2-321]). Despite the risk of producing biased treatment estimates, other authors favor the use of non-randomized studies on the basis that these can lead to results which may be compared with those reported in RCTs ([@b3-co-2-321]). Therefore, sources of existing observational data can provide valuable information. Also, RCTs are generally conducted under strict protocol conditions that differ from everyday practice. Consequently, some authors assert that randomized studies do not provide information of much relevance to decision-makers ([@b13-co-2-321]). Thus, while most clinical researchers regard observational studies as exploratory tools yielding results that need to be confirmed by RCTs, non-randomized studies need to be performed after RCTs to assess the external validity of RCT findings. Our database analysis should be interpreted in this manner.

On the information available, we observed no socio-demographic differences between patients receiving CAIs or alpha-2 agonists, except for time since diagnosis and duration of follow-up, despite the lack of treatment randomization. The latter is explained by the earlier Market Access Authorization of brimonidine (European Medicines Agency). General and ocular comorbidity differences between the treatment groups were not related to clinical outcomes and no adjustment was necessary. Nonetheless, we analyzed treatment failure both with and without adjustment and obtained very similar results, confirming the robustness of our findings. In addition, we used a propensity score analysis which is well accepted by health authorities (Yue 2004). This approach follows the recommendations issued by the *British Medical Journal* ([@b22-co-2-321]; [@b24-co-2-321]; [@b27-co-2-321]).

As far as possible, taking into account the information available in the UK GPRD database, we gave due attention to controlling selection bias and confounding factors. First, these matters are clinically relevant as both drug classes had the same indications. Moreover, the choice between a CAI, or an alpha-2 agonist combined with a PGA, after the latter monotherapy has failed, is clinically important. Second, data were collected on available factors known to be confounded with treatment persistence, eg, age as a surrogate endpoint of glaucoma severity, eye, and general comorbidities. Data on other confounding factors were not recorded in the database (eg, race and IOP at treatment initiation). However, as the estimated propensity score may be regarded as a latent variable, summarizing disease severity, the reported findings were duly adjusted. Third, baseline comparison was performed and showed no major differences between the treatment groups. Fourth, none of the few unbalanced variables was linked to treatment persistence. Hence, our propensity score might have led to some over-adjustment, despite which the adjusted results remained statistically significant. Lastly, two adjustment procedures, ie, regression (not reported) and propensity scores, were used and neither showed any major change of treatment effect.

The larger number of patients treated with a CAI could have introduced a channelling bias, ie, the few severe cases would have been treated with the most effective drug. We believe that two major factors would explain this imbalance: (1) two CAIs were marketed (brinzolamide and dorzolamide), as compared to one of the alpha-2 agonists (brimonidine), and (2) dorzolamide market authorization and access preceded brimonidine by 1 year.

The number of drugs following CAI or alpha-2 agonist treatment failure was somewhat greater after the alpha-2 agonists, suggesting a more frequent occurrence of severe cases in the latter patient group. From a strict standpoint, treatment group imbalance should be considered at the initiation of treatments. Therefore, we did not regard subsequent events as factors influencing treatment persistence. Also, the initiation of a rescue treatment depends on the previous treatment and the choice should take into account the pharmaco-dynamics of the drugs concerned, which differ between CAIs and alpha-2 agonists. Lastly, the number of patients given surgery or laser therapy as rescue treatments, ie, the most severe cases, was similar.

Data management was performed 'blind', before any patient was selected, with respect to the general glaucoma database where all types of treatment were pooled together. This allowed us to minimize bias when comparing treatments. Also, this approach was meaningful as the compared glaucoma drugs were homogenously distributed, hence choices made at a global level should not have impacted on any specific treatment. We performed sensitivity analyses on subsets of the entire glaucoma database (eg, when selecting the 100-day threshold) because our data management programs required intensive computer resources (some files exceeded 15 millions lines). Accordingly, we believe that our data management was fair and did not systematically bias treatment comparisons.

Treatment failure was signaled by a change of treatment, ie, adding, stopping or replacing glaucoma medication, surgery or laser therapy, as is common practice with glaucoma analyses of claim data ([@b8-co-2-321]; [@b23-co-2-321]; [@b4-co-2-321]; [@b39-co-2-321]).

We found a significantly lower rate of treatment failure with CAIs + PGAs over a 4 year period, according to our outcome definition. The comparison between treatment persistence and clinical efficacy is not straightforward since the former encompasses several dimensions which are usually controlled in clinical trials (eg, treatment delivery, compliance, efficacy, safety). Our results could be compared to those of [@b11-co-2-321] and [@b25-co-2-321], who reported randomized, masked studies, comparing dorzolamide and brimonidine. Both sets of authors concluded that the treatments produced equivalent IOP control. Our different observation may be explained by several factors. First, we studied treatments in contrast to the two randomized trials, which concerned second-line treatments. Second, our study involved large patient populations recorded in the UK-GPRD which provided greater power to observe small significant differences. Third, treatment acceptability may play a role. Although Stewart et al found both treatments to be well tolerated and without significant effects on safety parameters ([@b31-co-2-321]), [@b38-co-2-321] observed significantly more stinging and burning with dorzolamide (CAI) (p \< 0.02) and more frequent dry eyes with brimonidine (alpha-2 agonist) (p = 0.04) (Whiston et al 2004). Accordingly, in everyday practice it is possible that treatment failure may be related to unwanted effects that patients will not tolerate. Specific patient chart data should be collected to test this hypothesis.

The costs of CAIs + PGA were higher than the ones of alpha-2 + PGA while the cost of one bottle of brimonidine was higher (about +20%) than the average cost of the two CAIs participating in the analysis. This was explained by the longer treatment persistence of CAIs. Treatment failure leads to higher costs ([@b7-co-2-321]) as confirmed, here, by the nature of the rescue treatment which in most cases comprised the more costly prostaglandin analogues. Conversely, medications that would lower the failure rate should reduce the costs of patients who receive them. The annual failure rate with CAIs was significantly lower over 4 years than for alpha-2 agonists. Hence, by delaying the need for more expensive glaucoma treatments, CAIs would eventually become less expensive than alpha-2 agonists. Results for adjusted and non-adjusted costs were presented because the follow-up time for patients given CAIs was longer than with alpha-2 agonists. Cost differences during either drug regimen remained non-significant both with and without adjustment.

Our analysis has the following limitations. First, as prescription renewal was not clearly documented we fixed the average renewal period at 100 days, corresponding approximately to three eye-drop bottles. An eye-drop bottle contains fluid for 28 days according to the summary of product characteristics ([@b35-co-2-321]), with extra fluid to replace for poor instillations by elderly persons ([@b28-co-2-321]). Thus, our assumption of 100 days per prescription appears reasonable. In order to confirm our findings, experimental designs with prospective data collection are required to document in detail treatment switches and the reasons for switches. Hence, observational surveys recording treatment administration prospectively might be of scientific interest.

Second, reasons for modifying treatments are not documented in the UK-GPRD, and that limits a definitive understanding. Given this circumstance, it was assumed that treatment changes were made for reasons of tolerance or lack of efficacy.

Third, the main limitation of this study was its retrospective design, which precluded any verification of data accuracy. Conversely, we were able to exploit aspects of UK National Health Service regulations that restrict a patient's access to other physicians, provide longitudinal data, and ensure a high standard of documentation which does not always apply to other health organizations. Hence, we were able to document previous treatments and check group comparability accurately, even though the internal validity of our survey was not equal to that of a randomized clinical trial.

Conclusion
==========

According to the UK-GPRD information, glaucoma treatment with CAIs + PGAs was more persistent in everyday practice than alpha-2 agonists + PGAs. Patients continued longer with CAIs. During 4 years of treatment the daily costs of a patient receiving CAIs were similar to those of alpha-2 agonists.
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###### 

Patient demography and follow-up duration

  Variable                            Alpha-2 agonists n = 1,384   CAIs n = 4,792   p-value
  ----------------------------------- ---------------------------- ---------------- ---------
  Gender                                                                            
   Male                               47.8%                        47.5%            0.8466
   Female                             52.2%                        52.5%            
  Age (years)                         69.2 (12.0)                  68.9 (12.5)      0.6419
  Time since diagnosis (years)        4.08 \[2.94\]                4.51 \[3.47\]    \<0.001
  Mean duration of follow-up (days)   1,059.6 \[967\]              838.1 \[700\]    \<0.001

**Note:** (sd) \[median\]

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.

###### 

Eye and general comorbidities -- UK GPRD prevalence rates

  Comorbity                                                         Alpha-2 agonists   CAIs            p-value
  ----------------------------------------------------------------- ------------------ --------------- ---------
  **Ocular comorbidity**                                                                               
  Anterior eye structural changes                                   273 (19.7%)        1,015 (21.2%)   0.2403
  Congenital eye disorders                                          10 (0.7%)          36 (0.8%)       0.9129
  Ocular infections, irritations and inflammations                  444 (32.1%)        1,459 (30.4%)   0.2461
  Ocular injuries                                                   20 (1.4%)          66 (1.4%)       0.8496
  Ocular neuro-muscular disorders                                   14 (1.0%)          55 (1.1%)       0.6711
  Ocular sensory symptoms                                           12 (0.9%)          15 (0.3%)       0.0059
  Retina, choroid and vitreous hemorrhages and vascular disorders   101 (7.3%)         319 (6.7%)      0.4043
  Ocular hemorrhages and vascular disorders                         64 (4.6%)          177 (3.7%)      0.1153
  Vision disorders                                                  262 (18.9%)        884 (18.4%)     0.6838
  **General comorbidity**                                                                              
  Blood and lymphatic disorders                                     162 (11.7%)        618 (12.9%)     0.2399
  Cardiac disorders                                                 698 (50.4%)        2,184 (45.6%)   0.0014
  Congenital and genetic disorders                                  73 (5.3%)          279 (5.8%)      0.4389
  Ear disorders                                                     645 (46.6%)        2,224 (46.4%)   0.8989
  Endocrine disorders                                               289 (20.7%)        978 (20.4%)     0.7900
  Gastrointestinal                                                  912 (65.9%)        3,182 (66.4%)   0.7256
  Liver disorder                                                    69 (5.0%)          228 (4.8%)      0.7274
  Immune system disorders                                           700 (50.6%)        2,182 (45.5%)   \<0.001
  Infections                                                        1,036 (74.9%)      3,524 (73.5%)   0.3264
  Injuries                                                          630 (45.5%)        2,144 (44.7%)   0.6078
  Metabolism and nutrition disorders                                633 (45.7%)        2,212 (46.2%)   0.7808
  Musculo-skeletal disorders                                        1,083 (78.3%)      3,722 (77.7%)   0.6472
  Neoplasm benign and malignant                                     477 (34.5%)        1,709 (35.7%)   0.4116
  Nervous system disorders                                          892 (64.5%)        2,898 (60.5%)   0.0075
  Psychiatric disorders                                             547 (39.5%)        2,038 (42,5%)   0.0458
  Renal and urinary disorders                                       543 (39.2%)        1,879 (39.2%)   0.9877
  Respiratory disorders                                             1,079 (78.0%)      3,570 (74.5%)   0.0085
  Skin and subcutaneous tissue disorders                            932 (67.3%)        3,212 (67.0%)   0.8274

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.

###### 

Adjusted failure rates over time according to treatment

  Duration of treatment                        Alpha-2 agonists   CAIs
  -------------------------------------------- ------------------ -------
  12 months                                    34.0%              41.2%
  24 months                                    16.4%              22.6%
  36 months                                    8.1%               12.7%
  48 months                                    3.5%               6.3%
  Time to 50% failure incidence rate (month)   6.5                8.5

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.

###### 

Resource utilization after CAI alpha-2 agonist treatment failure

  Rescue treatment          Alpha-2 agonists n = 1,319   CAIs n = 4,415   Total n = 5,734
  ------------------------- ---------------------------- ---------------- -----------------
  Number of drugs                                                         
   No drugs                 39 (3.0%)                    126 (2.9%)       165 (2.9%)
   Monotherapy              854 (64.7%)                  3,280 (74.3%)    4,134 (72.1%)
   2 drugs                  197 (14.9%)                  435 (9.9%)       632 (11.0%)
   3 drugs                  223 (16.9%)                  553 (12.5%)      776 (13.5%)
   4 drugs                  6 (0.5%)                     21 (0.5%)        27 (0.5%)
  Surgery                   32 (2.4%)                    110 (2.5%)       142 (2.5%)
  Laser therapy             7 (0.5%)                     16 (0.3%)        23 (0.4%)
  Drug classes                                                            
   Beta-blocker             270 (20.5%)                  1,529 (34.6%)    1,799 (31.4%)
   Prostaglandin analogue   845 (64.1%)                  2,732 (61.9%)    3,577 (62.4%)
   Alpha-2                  663 (50.3%)                  345 (7.8%)       1,008 (17.6%)
   CAI                      249 (18.9%)                  227 (5.1%)       476 (8.3%)

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.

###### 

Annual average cost of glaucoma according to the treatment (£: 2005)

  Cost item                                                Alpha-2 agonists               CAIs                            p-value
  -------------------------------------------------------- ------------------------------ ------------------------------- ------------
  Annual total costs from inclusion                        413.83 (700.37)                421.11 (762.14)                 0.7501
  Monthly total costs from inclusion                       34.01 (57.56)                  34.61 (62.64)                   0.7501
  Drugs                                                    23.83 (36.91)                  24.44 (36.93)                   \~1
   Monthly costs of drugs of study                         7.29 (15.21)                   9.19 (14.55)                    \<0.0001
   Monthly costs of other drugs                            16.54 (22.36)                  15.25 (23.24)                   0.0657
  Monthly costs of consultation                            8.01 (19.45)                   8.30 (20.11)                    0.6242
  Monthly costs of hospitalization-surgery-laser therapy   2.17 (16.12)                   1.88 (24.66)                    \~1
  **Mean daily costs unadjusted**                          **1.13 (1.92)**                **1.15 (2.09)**                 **0.7501**
  **Annual adjusted total costs**                          **440.63 \[401.27--480.0\]**   **413.37 \[392.32--434.41\]**   **0.2327**

**Note:** (sd) \[CI 95%\]

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.
